CA
GH icon

Calton & Associates’s Guardant Health GH Stock Holding History

Calton & Associates’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,597
Closed -$200K – 168
2023
Q2 		$200K Buy
+5,597
New +$161K 0.09% 196
2021
Q4 		– Sell
-1,921
Closed -$240K – 377
2021
Q3 		$240K Buy
1,921
+207
+12% +$24.6K 0.05% 338
2021
Q2 		$213K Sell
1,714
-59
-3% -$7.94K 0.04% 374
2021
Q1 		$271K Sell
1,773
-10
-0.6% -$1.51K 0.05% 304
2020
Q4 		$230K Sell
1,783
-20
-1% -$2.3K 0.04% 333
2020
Q3 		$202K Buy
+1,803
New +$165K 0.04% 317

Other funds holding GH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Calton & Associates's GH Position: Q3 2023 in Review

Calton & Associates sold out of Guardant Health (GH) in Q3 2023, closing a stake of 5,597 shares — an estimated $200K sold.

Calton & Associates first reported a position in GH in Q3 2020 and held it in 6 quarters. The position peaked at $271K in Q1 2021. 296 funds tracked by Wall St. Rank hold GH as of Q3 2023.

  • Calton & Associates reported no remaining Guardant Health position as of Q3 2023 after selling out during the quarter.
  • Calton & Associates sold 5,597 Guardant Health shares in Q3 2023, an estimated $200K.
  • Calton & Associates first reported a position in Guardant Health in Q3 2020 and held it in 6 quarters.
  • Calton & Associates's Guardant Health position peaked at $271K in Q1 2021.
  • 296 funds tracked by Wall St. Rank held Guardant Health as of Q3 2023.

Based on Calton & Associates's 13F filing for Q3 2023, filed 1 Nov 2023.